✦ LIBER ✦

235 SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1

✍ Scribed by Jacobson, Ira M.; Zeuzem, Stefan; Baykal, Tolga; Marinho, Rui T.; Poordad, Fred; Bourliere, Marc; Sulkowski, Mark; Wedemeyer, Heiner; Tam, Edward; Desmond, Paul V.; Jensen, Donald M.; Di Bisceglie, Adrian M.; Varunok, Peter; Hassanein, Tarek; Xiong, Junyuan; DaSilva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas

Book ID: 122219715
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 361 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)63286-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLL

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

✍ Zeuzem, S.; Jacobson, I.; Baykal, T.; Marinho, R.T.; Poordad, F.; Bourliere, M.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 152 KB

475 SAPPHIRE I: Phase 3 Placebo-Controll

475 SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naïve Adults With Hepatitis C Virus Genotype 1

✍ Kowdley, Kris V.; Feld, Jordan J.; Coakley, Eoin; Sigal, Samuel; Nelson, David R 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 825 KB

O60 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLL

O60 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAIVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

✍ Feld, J.J.; Kowdley, K.V.; Coakley, E.; Sigal, S.; Nelson, D.; Crawford, D.; Wei 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB

929e PEARL-II: Randomized Phase 3 Trial

929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients

✍ Andreone, Pietro; Colombo, Massimo; Enejosa, Jeffrey V.; Koksal, Iftihar; Ferenc 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Su1061 Pearl-IV: a 12-Week Regimen of AB

Su1061 Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates≥90% in Treatment-Naïve Adults Infected With Hepatitis C Virus Genotype 1A

✍ Bernstein, David; Lalezari, Jacob; Luo, Yan; Box, Terry D.; Younes, Ziad H.; Gre 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 544 KB

O163 TURQUOISE-II: SVR12 RATES OF 92–96%

O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)

✍ Poordad, F.; Hezode, C.; Trinh, R.; Kowdley, K.V.; Zeuzem, S.; Agarwal, K.; Shif 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 152 KB